Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270831
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
1000±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270831
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-N-methylacetamido}acetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL503983
Type:
Small organic molecule
Emp. Form.:
C69H98N18O16S2
Mol. Mass.:
1499.757
SMILES:
CC(C)C[C@H](NC(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:80.82,95.100,28.36,50.60,42.44,4.4,74.78,wD:61.64,17.25,46.48,99.103,(29.75,3.77,;29.75,2.23,;31.09,1.45,;28.41,1.45,;28.41,-.09,;27.08,-.86,;25.75,-.09,;25.75,1.45,;24.42,-.86,;23.08,-.1,;23.09,1.44,;21.75,-.87,;21.75,-2.41,;20.42,-.1,;19.08,-.87,;17.75,-.1,;17.75,1.44,;16.42,-.87,;16.42,-2.41,;17.75,-3.18,;19.08,-2.41,;20.41,-3.18,;20.42,-4.72,;19.09,-5.49,;17.75,-4.73,;15.09,-.1,;13.76,-.88,;13.76,-2.42,;12.42,-.11,;12.42,1.44,;13.76,2.2,;15.17,1.58,;16.19,2.73,;15.42,4.06,;13.91,3.73,;11.08,-.86,;9.74,-.09,;9.74,1.45,;8.41,-.87,;7.08,-.08,;5.75,-.87,;5.75,-2.41,;4.42,-.1,;3.08,-.87,;1.75,-.1,;1.75,1.45,;.42,-.87,;-.91,-.1,;-2.24,-.88,;-2.24,-2.42,;-3.58,-.11,;-3.58,1.44,;-2.24,2.2,;-.9,1.43,;.43,2.2,;.43,3.75,;-.92,4.51,;-2.24,3.73,;-4.92,-.86,;-6.26,-.1,;-6.26,1.44,;-7.59,-.88,;-8.94,-.08,;-7.59,-2.41,;-6.26,-3.18,;-6.26,-4.72,;-4.92,-5.49,;-4.92,-7.03,;-6.27,-7.77,;-3.6,-7.79,;.42,-2.41,;1.97,-2.41,;-1.12,-2.4,;.42,-3.95,;4.42,1.45,;3.09,2.21,;5.75,2.21,;29.74,-.86,;29.74,-2.4,;31.08,-.09,;32.41,-.86,;33.74,-.09,;33.74,1.45,;32.42,2.22,;32.41,3.75,;33.75,4.53,;33.75,6.07,;35.08,3.77,;35.09,2.23,;32.41,-2.4,;31.08,-3.17,;33.74,-3.17,;35.32,-2.64,;36.34,-3.98,;35.39,-5.36,;33.99,-4.67,;32.76,-5.6,;31.35,-5,;32.74,-7.14,;31.41,-7.9,;30.08,-7.12,;28.74,-7.88,;31.39,-9.44,;30.04,-10.2,;32.71,-10.23,)|
Structure:
Search PDB for entries with ligand similarity: